CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo‐controlled study
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Aims: Macrophage recruitment through C‐C motif chemokine receptor‐2 (CCR2) into adipose tissue is believed to play a role in the development of insulin resistance and type 2 diabetes mellitus (T2DM). The objective of this Phase 2 proof‐of‐concept study was to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of JNJ‐41443532, an orally bioavailable CCR2 antagonist, in patients with T2DM. Methods: This was a 4‐week, double‐blind, placebo‐controlled, randomized, multicenter study. A total of 89 patients were randomized to receive either 250‐ or 1000‐mg of JNJ‐41443532 twice daily, 30‐mg of pioglitazone once daily (reference arm), or placebo. The primary endpoint was change from baseline in 23‐h weighted mean glucose (WMG); secondary endpoints included change from baseline in fasting plasma glucose (FPG), insulin resistance (Homeostatic Model Assessment [HOMA‐IR]), insulin secretion (HOMA‐%B) and body weight. Results: Absorption of JNJ‐41443532 into the systemic circulation occurred at a median t max of 2 h, and the mean t ½ was approximately 8 h for both doses; plasma systemic exposures increased slightly more than dose‐proportionally. After 4 weeks, reductions in 23‐h WMG and FPG were observed in all treatment groups compared with placebo and were significantly lower for 250‐mg JNJ‐41443532 and pioglitazone. HOMA‐IR was lower for all treatment groups, but significantly lower only for pioglitazone. Conversely, HOMA‐%B was increased for all groups, but significantly increased only for 250‐mg JNJ‐41443532. All groups, including placebo, had decreased body weight over time. There were no clinically significant findings during routine safety assessments and the incidence of treatment‐emergent adverse events was similar across all groups. Conclusions: Administration of JNJ‐41443532 resulted in modest improvement in glycaemic parameters compared with placebo, and was generally well tolerated in patients with T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boring, L., Gosling, J., Cleary, M., & Charo, I. F. (1998) · Nature · doi:10.1038/29788 · Cited by 1,965
Interleukin-1-receptor antagonist in type 2 diabetes mellitus
Larsen, C. M., Faulenbach, M., Vaag, A., Vølund, A., Ehses, J. A., Seifert, B., Mandrup-Poulsen, T., & Donath, M. Y. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065213 · Cited by 1,798
Inflammatory Cytokines and the Risk to Develop Type 2 Diabetes
Spranger, J., Kroke, A., Möhlig, M., Hoffmann, K., Bergmann, M. M., Ristow, M., Boeing, H., & Pfeiffer, A. F. H. (2003) · Diabetes · doi:10.2337/diabetes.52.3.812 · Cited by 1,493
Monnier, L., Lapinski, H., & Colette, C. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.881 · Cited by 1,461 · cited 1×
“7% reduction in HbA1c, which is considered to be a clinically meaningful effect [20,21].”
BackgroundRelationship between Adipocyte Size and Adipokine Expression and Secretion
Skurk, T., Alberti-Huber, C., Herder, C., & Hauner, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-1055 · Cited by 1,288 · cited 1×
“White adipose tissue is a metabolically active organ with the ability to secrete a variety of chemokines and pro-inflammatory cytokines [2,3].”
BackgroundSustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes
Larsen, C. M., Faulenbach, M., Vaag, A., Ehses, J. A., Donath, M. Y., & Mandrup-Poulsen, T. (2009) · Diabetes Care · doi:10.2337/dc09-0533 · Cited by 401
Lumeng, C. N., Deyoung, S. M., & Saltiel, A. R. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00284.2006 · Cited by 359
Measuring and estimating insulin resistance in clinical and research settings
Matsuda, M. (2010) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2009.07.007 · Cited by 80 · cited 1×
“disposition index) that would provide greater insight into its mechanism of action [35].”
Background
Cited by
Metabolic Inflammation and Insulin Resistance in Obesity
Wu, H., & Ballantyne, C. M. (2020) · Circulation Research · doi:10.1161/circresaha.119.315896 · Cited by 1,059
Targeting adipose tissue in the treatment of obesity-associated diabetes
Kusminski, C. M., Bickel, P. E., & Scherer, P. E. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.75 · Cited by 678
Regulation of metabolism by the innate immune system
Lackey, D. E., & Olefsky, J. M. (2016) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.189 · Cited by 667
Current and future pharmacological therapies for NAFLD/NASH
Sumida, Y., & Yoneda, M. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-017-1415-1 · Cited by 667
Management of NAFLD: a stage-based approach
Rinella, M. E., & Sanyal, A. J. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.3 · Cited by 385
Metadata
- Authors
- Di Prospero, N. A., Artis, E., Andrade‐Gordon, P., Johnson, D. L., Vaccaro, N., Xi, L., & Rothenberg, P.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2014-05-25
- Volume
- 16
- Issue
- 11
- Pages
- 1055-1064
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2081095734
- Cited by
- 45
- References
- 8
- FWCI
- 3.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo‐controlled study. https://app.cochat.ai/papers/10.1111/dom.12309
- The paper
- Di Prospero, N. A., Artis, E., Andrade‐Gordon, P., Johnson, D. L., Vaccaro, N., Xi, L., & Rothenberg, P. (2014). CCR2 antagonism in patients with type 2 diabetes mellitus: a randomized, placebo‐controlled study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.12309
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.